Compare TG Therapeutics Inc (TGTX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Vanguard Total International Stock Index Fund ETF trades at $84.78. Which is the better fit depends on your goals.
| TGTX | VXUS | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $87.06 |
52-Week Low | $26.39 | $68.24 |
Enterprise Value | $8.50B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure to over 8,700 non-U.S. stocks across developed and emerging markets. Recent institutional buying activity includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026. Technical indicators show neutral oscillators but bearish momentum with support at $82 and resistance at $84.
The outlook remains cautious due to global economic uncertainty, though VXUS offers diversification benefits for U.S.-centric portfolios. Key risks include currency fluctuations and emerging market volatility. Analyst sentiment is mixed with some recommending international diversification while others caution about growth/inflation dynamics in global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
